Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2018

View Archived Issues

Disconnecting bone building from resorption may be osteoporosis strategy

Myocardial regeneration outcomes using WJMSCs presented from pilot cohort of CIRCULATE-AMI study

Identification of a mosquito salivary gland protein that partially limits malaria transmission

MPO-0112 ameliorates scopolamine-induced cognitive impairment in mice

Ozalin becomes the first oral pediatric sedative to receive marketing authorization in Europe

BioArctic enters research collaboration with Brain Biomarker Solutions in Alzheimer's

New sphingolipid-biased phenotypic approach for the discovery of new targets and new leads

XBiotech presents positive interim data for initial cohort of bermekimab pilot study

FDA approves subcutaneous Actemra for active systemic juvenile idiopathic arthritis

Bone Therapeutics reports final data from phase I/IIa study of ALLOB in delayed-union fractures

Merck & Co. evaluating MK-1654 in phase I/II study in healthy preterm and full-term infants

FDA approves Lumoxiti for relapsed or refractory hairy cell leukemia

Patient recruitment ongoing in phase I study of INCAGN-02390

TD-1473 being evaluated in phase II study in patients with active Crohn's disease

Natera enters agreement with Bristol-Myers Squibb for use of Signatera ctDNA assay in Opdivo trial

Biogen begins clinical evaluation of BIIB-078 in C9ORF72-associated ALS

Arrowhead Pharmaceuticals patents RNAi for thromboembolic disorders

GSK begins first-in-human study of GSK-3439171A

Hanyang University presents new MAPK 10 inhibitors

Merck & Co. synthesizes new IDO1 inhibitors

Monash University and GSK present discovery of novel compound for treatment of Chagas disease

NTZ-2020 and NTZ-2027 as promising new candidates for the treatment and diagnosis of CNS disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...